pituitary adenoma/prolactin secreting (prolactinoma)

From Aaushi
Jump to navigation Jump to search

Epidemiology

Pathology

  • women
    • almost always small tumors (microadenomas)
    • clinical course is benign
    • tumors rarely enlarge
  • men
    • generally large tumors (macroadenomas)
    • often aggressive tumors

Genetics

  • associated with defects in AIP

Clinical manifestations

Laboratory

Diagnostic procedures

Radiology

Complications

Differential diagnosis

Management

* dopaminergic agonists decrease size of prolactinomas > 50% in 80-90% of patients[1]

More general terms

Additional terms

References

  1. Jump up to: 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 Medical Knowledge Self Assessment Program (MKSAP) 11, 15, 16, 17, 18. American College of Physicians, Philadelphia 1998, 2009, 2012, 2015, 2018.
  2. Klibanski A Clinical practice. Prolactinomas. N Engl J Med. 2010 Apr 1;362(13):1219-26 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20357284
  3. Mann WA Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach. Eur J Clin Invest. 2011 Mar;41(3):334-42.
  4. Jump up to: 4.0 4.1 NEJM Knowledge+
  5. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) web page "Prolactinoma" http://www.niddk.nih.gov/health/endo/pubs/prolact/prolact.htm

Database